DXS INTERNATIONAL PLC
Notification of Director / PDMR Dealing
The Board of DXS International plc (the “Company”), the AQSE Growth Market quoted clinical decision support developer and supplier of clinical decision support systems has received notification and notified the market that on 4 December 2023 Mr Bob Sutcliffe purchased a total of 400,000 Ordinary Shares in the Company at a price of 2.5p per share on behalf of himself and others.
One of the other persons acquiring beneficial ownership of Ordinary Shares as a result of Mr Sutcliffe’s purchase is David Immelman, the DXS Chief Executive, who has acquired a beneficial interest in 40,000 Ordinary Shares. Following this transaction Mr Immelman, and persons connected to him, have an interest in DXS Ordinary Shares of 6,563,829 Ordinary Shares representing 10.25% of the issued share capital of the Company.
Details of the person discharging managerial responsibilities / person closely associated
Reason for the notification
Initial notification /Amendment
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
DXS INTERNATIONAL PLC
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
Description of the financial instrument, type of instrument
Ordinary Shares of 0.33p each
Nature of the transaction
Issue of new shares
Price(s) and volume(s)
- Aggregated volume
Date of the transaction
4 December 2023
Place of the transaction
Aquis Stock Exchange
The Directors of DXS International plc accept responsibility for this announcement.
David Immelman (Chief Executive)
0207 101 7676
020 3764 2341
Note to Editors:
DXS International presents up to date treatment guidelines and recommendations, from Clinical Commissioning Groups and other trusted NHS sources, to doctors, nurses and pharmacists in their workflow and during the patient consultation. This effective clinical decision support ultimately translates to improved healthcare outcomes delivered more cost effectively which should significantly contribute towards the NHS achieving its projected efficiency savings.